论文部分内容阅读
目的 通过检测正常人、初治和治疗后完全缓解 ( CR)之恶性淋巴瘤患者血清可溶性细胞间粘附分子 - 1 ( s ICAM- 1 )水平 ,探讨其临床意义。方法 采用酶联免疫吸附法 ( ELISA)检测 2 5例正常人和 2 3例恶性淋巴瘤患者血清 s ICAM- 1含量。结果 初治恶性淋巴瘤患者血清 s ICAM- 1含量高于正常人 ( P <0 .0 1 )和 CR期恶性淋巴瘤患者 ( P <0 .0 5 ) ,而 CR期恶性淋巴瘤患者也高于正常人 ,但无显著性差异 ( P >0 .0 5 )。结论 检测血清 s ICAM- 1的含量对恶性淋巴瘤的诊断、病情观察及疗效判断可能有一定的临床意义。
Objective To investigate the clinical significance of serum soluble intercellular adhesion molecule-1 (sICAM-1) levels in normal, initial, and post-treatment CR patients with malignant lymphoma. Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect serum ICAM-1 levels in 25 normal and 23 malignant lymphoma patients. Results Serum levels of sICAM-1 in patients with newly diagnosed malignant lymphoma were higher than those in normal controls (P < 0.01) and malignant lymphoma patients with CR (P <0.05). Patients with malignant lymphoma at CR were also high. In normal subjects, there was no significant difference (P > 0.05). Conclusion The detection of serum sICAM-1 may have certain clinical significance in the diagnosis of malignant lymphoma, observation of disease condition and judgment of therapeutic effect.